
Supplementary Material

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials

**Alberico L. Catapano, L. Veronica Lee, Michael J. Louie, Desmond Thompson,
Jean Bergeron, Michel Krempf**

Supplementary Table 1. Further details of statin dose usage

Data are n (%)		Pool 1 HIGH FH + LONG TERM (n=2448)		Pool 2 COMBO I + FH I + FH II (n=1051)		Pool 3 COMBO II + OPTIONS I + OPTIONS II (n=1130)	
Statin	Dose	ALI (n=1625)	PBO (n=823)	ALI (n=699)	PBO (n=352)	ALI (n=686)	EZE (n=444)
Moderate-dose statin		542 (33.4)	271 (32.9)	108 (15.5)	43 (12.2)	208 (30.3)	152 (34.2)
Atorvastatin	20 mg	138 (8.5)	62 (7.5)	19 (2.7)	7 (2.0)	83 (12.1)	66 (14.9)
	30 mg	2 (0.1)	0	0	0	1 (0.1)	0
Rosuvastatin	10 mg	66 (4.1)	34 (4.1)	14 (2.0)	5 (1.4)	61 (8.9)	62 (14.0)
	15 mg	0	1 (0.1)	1 (0.1)	0	0	0
Simvastatin	40 mg	332 (20.4)	171 (20.8)	73 (10.4)	30 (8.5)	62 (9.0)	22 (5.0)
	50 mg	0	1 (0.1)	0	0	0	0
	60 mg	4 (0.2)	2 (0.2)	1 (0.1)	1 (0.3)	1 (0.1)	2 (0.5)
Low-dose statin		297 (18.3)	151 (18.3)	47 (6.7)	26 (7.4)	47 (6.9)	27 (6.1)
Atorvastatin	5 mg	0	0	2 (0.3)	0	0	0
	5.7 mg	1 (0.1)	0	0	0	0	0
	10 mg	67 (4.1)	33 (4.0)	7 (1.0)	3 (0.9)	5 (0.7)	6 (1.4)
Rosuvastatin	2.5 mg	1 (0.1)	0	0	2 (0.6)	0	0
	5 mg	22 (1.4)	10 (1.2)	11 (1.6)	6 (1.7)	9 (1.3)	1 (0.2)
Simvastatin	5 mg	2 (0.1)	1 (0.1)	0	1 (0.3)	0	0
	10 mg	45 (2.8)	21 (2.6)	3 (0.4)	3 (0.9)	5 (0.7)	4 (0.9)
	20 mg	153 (9.4)	85 (10.3)	24 (3.4)	11 (3.1)	28 (4.1)	16 (3.6)
	30 mg	6 (0.4)	1 (0.1)	0	0	0	0

ALI, alirocumab, EZE, ezetimibe, PBO, placebo.

Supplementary Table 2. Absolute change from baseline in LDL-C at Week 24:
Subgroup analysis by statin type and dose

Study pool	Subgroup	N	Absolute change from baseline LS mean (SE)	
			Control	Alirocumab
A) Atorvastatin				
ALI 150 vs PBO	10 mg	98	-4.2 (6.1)	-69.6 (4.3)
	20 mg	195	-8.2 (4.6)	-70.9 (3.0)
	40 mg	362	-1.0 (3.3)	-73.7 (2.3)
	80 mg	264	-4.6 (4.0)	-76.2 (2.6)
ALI 75/150 vs PBO	40 mg	140	-1.7 (5.2)	-67.6 (4.1)
	80 mg	194	10.1 (4.6)	-65.4 (3.3)
ALI 75/150 vs EZE	20 mg	145	-23.8 (4.2)	-50.5 (3.7)
	40 mg	260	-25.6 (3.2)	-55.8 (2.6)
	80 mg	136	-21.3 (4.8)	-53.2 (3.4)
B) Rosuvastatin				
ALI 150 vs PBO	5 mg	30	6.6 (11.7)	-75.1 (8.8)
	10 mg	100	-14.2 (6.6)	-80.8 (4.7)
	20 mg	213	-9.3 (4.5)	-80.3 (3.2)
	40 mg	255	-2.6 (3.9)	-80.1 (3.0)
ALI 75/150 vs PBO	20 mg	149	-0.2 (5.9)	-67.3 (3.8)
	40 mg	302	11.1 (3.8)	-63.8 (2.7)
ALI 75/150 vs EZE	10 mg	121	-21.5 (4.9)	-56.3 (4.8)
	20 mg	221	-24.3 (3.9)	-52.3 (3.2)
	40 mg	49	-21.4 (8.9)	-53.9 (6.3)
C) Simvastatin				
ALI 150 vs PBO	10 mg	68	2.1 (7.0)	-66.2 (4.8)
	20 mg	233	-1.7 (3.6)	-73.0 (2.7)

	40 mg	495	-4.2 (2.5)	-74.6 (1.8)
	80 mg	76	-1.7 (5.8)	-71.9 (5.0)
ALI 75/150 vs PBO	20 mg	35	-12.9 (10.6)	-51.8 (7.2)
	40 mg	104	-5.3 (6.2)	-62.1 (4.1)
	80 mg	30	13.5 (9.1)	-54.1 (8.9)
ALI 75/150 vs EZE	20 mg	44	-20.1 (7.9)	-42.0 (6.1)
	40 mg	79	-22.7 (6.6)	-58.3 (4.1)
	80 mg	15	-19.8 (17.1)	-47.4 (10.1)

ALI, alirocumab; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; LS, least squares; PBO, placebo; SE, standard error.